Adjuvant therapy with Imatinib for gastrointestinal stromal tumors has been evaluated in multiple trials. ACOSOG Z9000 was a single arm phase II trial that determined that use of Imatinib as adjuvant treatment for one year in patient at high risk for recurrence (incomplete idea?). 107 patients with completely resected GISTs =10 cm in size, ruptured, hemorrhaging, or multifocal GISTs (<5 sites total) received 400 mg Imatinib daily for one year. Given this high rate of recurrence, the ability to evaluate a patients risk of recurrence and the benefit of adjuvant therapy after surgery is necessary.
Top journals are typically peer-reviewed journals that publish theoretical discussions and articles that critically review already published work. Top journals serve as an important forum for researchers and academicians from where they can access important information about recent developments in their field.
Last date updated on December, 2020